NCT06968910View on ClinicalTrials.gov

CBD-based Therapy to Attenuate Non-bacterial Prostatitis Symptoms

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

January 1, 2025

Conditions
Prostatitis
Interventions
DEVICE

CANNEFF® SUP rectal suppositories

CANNEFF® SUP suppositories with cannabidiol (CBD = 100 mg) and hyaluronic acid (HA = 6.6 mg) as active ingredients

Trial Locations (1)

779 00

Department of Urology, University Hospital Olomouc, Czech Republic, Olomouc

All Listed Sponsors
collaborator

CB21 Pharma Ltd.

UNKNOWN

lead

Palacky University

OTHER